在类风湿性关节炎中与疾病修饰性抗风湿药物相关的恶性瘤风险:使用FAERS数据库进行药监测分析
Wan Xiong1,2, Yilin Li3, Lin Hu1,2
1Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Frontiers in pharmacology
|November 28, 2024
概括
用于类风湿性关节炎的疾病修饰性抗风湿药物 (DMARD) 与各种恶性瘤有关. 与其他类型相比,向合成DMARD的风险明显更高,癌症发病速度更快.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
背景情况:
- 改变疾病的抗风湿药物 (DMARDs) 对于治疗类风湿性关节炎至关重要.
- 随着时间的推移,恶性瘤报告与DMARD使用有关.
- 了解不同类型的DMARD的特定风险对于患者安全至关重要.
研究的目的:
- 调查各种疾病修饰性抗风湿药物 (DMARD) 与患恶性瘤的风险之间的关联.
- 分析食品和药物管理局不良事件报告系统 (FAERS) 的数据,以确定潜在的药物事件关系.
- 为了比较不同类型的DMARD的恶性瘤风险概况.
主要方法:
- 利用了2019年1月至2023年12月的FAERS数据.
- 进行了不成比例性分析,以评估每个药物事件对的恶性瘤风险.
- 采用多变量逻辑回归来控制潜在的混因素,并分析恶性瘤发病的时间.
主要成果:
- 确定了17412份与DMARD相关的恶性瘤不良事件报告,其中198个是积极信号.
- 皮肤状细胞癌,乳腺癌和淋巴增殖性疾病显示出显著的关联.
- 针对性合成DMARD与更广泛的恶性瘤相关,并且与传统合成DMARD (3.58-7.08年) 相比,中位数发病时间更短 (0.83-1.67年).
结论:
- 改变疾病的抗风湿药物 (DMARDs) 与恶性瘤的不同风险有关.
- 针对性合成DMARDs显示出明显更高的风险和早期发病的恶性瘤.
- 鉴定出了新的恶性瘤信号,需要进一步的研究来验证.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:20Rheumatic Heart Disease IV: Nursing Management
4
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
4
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
7
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
7
01:23Rheumatic Heart Disease I: Introduction
3
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
3